Beta Thalassemia clinical trials

Explore recruiting beta thalassemia clinical trials.

Recruiting beta thalassemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Beta Thalassemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A single arm, open label, multicenter, single-dose, phase 2b clinical study evaluating efficacy and safety of gene therapy using autologous CD34+ hematopoietic stem cells transduced with the GLOBE lentiviral vector using an improved transduction protocol in subjects with transfusion-dependent beta-thalassemia.

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Long-Term Follow-up of Subjects With Transfusion-Dependant β-Thalassemia Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector

Germany, France, Italy, Greece

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha or Beta Thalassemia (ENERGIZE-T)

France, Netherlands, Italy, Germany, Denmark, Bulgaria +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non–Transfusion-Dependent Alpha or Beta Thalassemia (ENERGIZE)

Greece, Netherlands, Bulgaria, Denmark, Spain, Italy +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Subcutaneously Administered REGN7999 (An Inhibitor of TMPRSS6) in Participants with Iron Overload Due to Non-Transfusion Dependent β-Thalassemia.

Greece, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Beta Thalassemia trials by city

Beta Thalassemia in Toronto Beta Thalassemia in Vancouver Beta Thalassemia in Montreal Beta Thalassemia in Calgary Beta Thalassemia in Edmonton Beta Thalassemia in Ottawa Beta Thalassemia in Winnipeg Beta Thalassemia in Quebec City Beta Thalassemia in Hamilton Beta Thalassemia in Kitchener Beta Thalassemia in London Beta Thalassemia in Halifax Beta Thalassemia in New York Beta Thalassemia in Los Angeles Beta Thalassemia in Chicago Beta Thalassemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease